EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY-NC 4.0

Baricitinib Improves Bone Properties and Biomechanics in Patients With Rheumatoid Arthritis: Results of the Prospective Interventional BARE BONE Trial

David Simon iD, Ioanna Minopoulou, Stephan Kemenes, Sara Bayat, Koray Tascilar iD, Melek Yalcin Mutlu, Larissa Valor-Méndez iD, Gerhard Krönke, Axel J Hueber, Georg Schett iD, Arnd Kleyer iD

Arthritis & Rheumatology · 2023

DOI: 10.1002/art.42617 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Arthritis & Rheumatology, 2023. Verfasst von David Simon und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander Universität (FAU) Erlangen-Nürnberg and Universitätsklinikum Erla…. Hauptthemen laut MEDLINE: Antirheumatic Agents, Arthritis, Rheumatoid. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Bundesministerium für Bildung und Forschung, Deutsche Forschungsgemeinschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Rheumatoid arthritis (RA) is characterized by erosive joint damage, deterioration of bone mass, and biomechanics. Preclinical evidence suggests a beneficial effect of Janus kinase inhibition (JAKi) on bone properties, but clinical data are scarce to date. In this study, we evaluated the effect of JAKi through baricitinib (BARI) on 1) volumetric bone mineral density (vBMD), bone microstructure, biomechanics, and erosion repair and 2) synovial inflammation in RA patients.

Methods

Prospective, single‐arm, interventional, open‐label, single‐center phase 4 study in RA patients with pathological bone status and clinical indication of JAKi (BARE BONE trial). Participants received BARI (4 mg/day) over 52 weeks. To assess bone properties and synovial inflammation, high‐resolution computed tomography scans and magnetic resonance imaging were performed at baseline (BL), week 24, and week 52. Clinical response and safety were monitored.

Results

Thirty RA patients were included. BARI significantly improved disease activity (Disease Activity Score in 28 joints using the erythrocyte sedimentation rate: 4.82 ± 0.90 to 2.71 ± 0.83) and synovial inflammation (RAMRIS synovitis score: 5.3 [4.2] to 2.7 [3.5]). We observed a significant improvement in trabecular vBMD with a mean change of 6.11 mgHA/mm 3 (95% confidence interval [95% CI] 0.01–12.26). Biomechanical properties also improved with mean change from baseline in estimated stiffness of 2.28 kN/mm (95% CI 0.30–4.25) and estimated failure load of 98.8 N (95% CI 15.9–181.7). The number and size of erosions in the metacarpal joints remained stable. No new safety signals with BARI treatment were observed.

Conclusion

Bones of RA patients improve with BARI therapy, as shown by an increase in trabecular bone mass and an improvement of biomechanical properties.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antirheumatic AgentsArthritis, RheumatoidHumansBiomechanical PhenomenaInflammationMagnetic Resonance ImagingProspective StudiesAzetidinesPurinesPyrazolesSulfonamides

Substanzen

Antirheumatic AgentsbaricitinibAzetidinesPurinesPyrazolesSulfonamides

Autor:innen und Institutionen

  • Department of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander Universität (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, and Deutsches Zentrum Immuntherapie, FAU Erlangen-Nürnberg and U…
  • Division of Rheumatology, Klinikum Nürnberg, Paracelsus Medical University, Nürnberg, Germany.

ORCID-Profile: David Simon, Koray Tascilar, Larissa Valor-Méndez, Georg Schett, Arnd Kleyer

Förderung

  • Bundesministerium für Bildung und Forschung
  • Deutsche Forschungsgemeinschaft

Zitieren

APA

Simon, D., Minopoulou, I., Kemenes, S., Bayat, S., Tascilar, K., Mutlu, M. Y., Valor-Méndez, L., Krönke, G., Hueber, A. J., Schett, G., & Kleyer, A. (2023). Baricitinib Improves Bone Properties and Biomechanics in Patients With Rheumatoid Arthritis: Results of the Prospective Interventional BARE BONE Trial. Arthritis & Rheumatology. https://doi.org/10.1002/art.42617

Vancouver

Simon D, Minopoulou I, Kemenes S, Bayat S, Tascilar K, Mutlu MY, et al. Baricitinib Improves Bone Properties and Biomechanics in Patients With Rheumatoid Arthritis: Results of the Prospective Interventional BARE BONE Trial. Arthritis & Rheumatology. 2023. doi:10.1002/art.42617

BibTeX
@article{Simon2023,
  author = {Simon, David and Minopoulou, Ioanna and Kemenes, Stephan and Bayat, Sara and Tascilar, Koray and Mutlu, Melek Yalcin and Valor-Méndez, Larissa and Krönke, Gerhard and Hueber, Axel J and Schett, Georg and Kleyer, Arnd},
  title = {Baricitinib Improves Bone Properties and Biomechanics in Patients With Rheumatoid Arthritis: Results of the Prospective Interventional BARE BONE Trial},
  journal = {Arthritis & Rheumatology},
  year = {2023},
  doi = {10.1002/art.42617}
}
Kostenlos starten →